Record quarter despite restructuring expenses

Press release

Record quarter despite restructuring expenses

Berlin, August 4, 2015. Berlin-based Eckert & Ziegler Strahlen- und Medizintechnik AG (ISIN DE0005659700), a specialist for isotope technology applications in medicine, science and industry, recorded one of its most-successful quarters ever in spite of considerable provisions being set aside for risk provisioning and the restructuring of ailing business units. The company's quarterly sales exceeded the EUR 35.0 million mark for the first time, and income after tax leapt to EUR 4.8 million following the sale of its interest in OctreoPharm Sciences GmbH.

In the first half of 2015 sales increased by EUR 7.1 million, or 11 %, to EUR 69.0 million. A majority of this amount, EUR 6.0 million, is due to the more favorable US dollar/euro exchange rate. EBIT almost doubled year on year to EUR 11.7 million. Profit for the first half of the year after taxes and minority interests increased by more than 100 % to EUR 7.5 million, or EUR 1.41 per share.

The Isotope Products segment benefited the most from the weak euro, while also recording a positive acquisition effect. Sales increased by 17 % to EUR 33.6 million. However, these effects did not result in any increase in profit, meaning that EBIT remained constant at EUR 7.1 million.

Sales in the Radiation Therapy segment increased by EUR 0.8 million due to currency effects to EUR 14.7 million, but were not enough to cover the cost base. Operating EBIT amounted to EUR -1.4 million. There were also positive currency effects of EUR 0.8 million and provisions of EUR 1.3 million for agreed restructuring measures and site closures. Segment EBIT therefore came in at EUR -1.9 million.

The sales of the Radiopharma segment rose by not only the currency effect but also organically, especially in the equipment division and with the gallium generators. The "Other operating income" item includes most of the proceeds arising from the sale of the OctreoPharm investment. As a result, EBIT increased many times over to EUR 7.4 million.

Price increases meant that the Others segment registered a slight increase in sales of EUR 0.1 million to EUR 3.5 million. EBIT increased significantly by EUR 0.6 million to EUR -0.8 million. The change is predominately due to the balance of a positive and a negative effect: The segment also received proceeds from the sale of the OctreoPharm investment. The segment was also impacted by a price increase announced in an important disposal channel, thereby further increasing provisions for waste material.

Cash flow from operating activities was up considerably year on year and achieved EUR 3.9 million, mainly due to the decrease in the Radiation Therapy segment's receivables.

For the fiscal year 2015, sales are expected to rise to over EUR 133 million, while an improvement in earnings to over EUR 2.00 per share is also being targeted.

The complete quarterly financial statements can be viewed under:
http://www.ezag.com/fileadmin/ezag/user-uploads/pdf/financial-reports/englisch/euz215e.pdf

About Eckert & Ziegler.
Eckert & Ziegler Strahlen- und Medizintechnik AG (ISIN DE0005659700), with approximately 700 employees, is one the world's largest providers of isotope technology for radiation therapy and nuclear medicine.
Contributing to saving lives.

For further information or questions, please contact:
Eckert & Ziegler AG, Karolin Riehle, Investor Relations Robert-Rössle-Str. 10, 13125 Berlin, Germany
Tel.: +49 (0) 30 / 94 10 84-138, karolin.riehle@ezag.de, www.ezag.com